Erika Doss, MD
Ophthalmology · Los Angeles, CANPI 1710391479
Payments from drug & device makers
Across 121 payments — averaging $30.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$705
- Tarsus Pharmaceuticals, Inc.$500
- Glaukos Corporation$373
- Sight Sciences, Inc.$272
- Carl Zeiss Meditec USA, Inc.$165
- plus $629 from 10 others
What the payments were for
- Food & beverage$3,630100%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $1,004 |
| Alcon | 13 | $705 |
| Tarsus Pharmaceuticals, Inc. | 23 | $500 |
| Glaukos Corporation | 6 | $373 |
| Sight Sciences, Inc. | 2 | $272 |
| Carl Zeiss Meditec USA, Inc. | 1 | $165 |
| Bausch & Lomb Americas Inc. | 3 | $163 |
| Aerie Pharmaceuticals, Inc. | 1 | $119 |
| Dompe US, Inc. | 4 | $84 |
| Sun Pharmaceutical Industries Inc. | 3 | $65 |
| Eyepoint US, Inc. | 2 | $57 |
| Oyster Point Pharma, Inc. | 3 | $53 |
| Mallinckrodt Enterprises LLC | 1 | $26 |
| Shire North American Group Inc | 1 | $25 |
| Amgen | 1 | $20 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,648 in reported general payments places this provider in the 65th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 240 | $157,953 |
| Cyclosporine | 340 | $97,100 |
| XdemvyLotilaner | 45 | $79,202 |
| Alphagan PBrimonidine Tartrate | 351 | $78,450 |
| Brimonidine Tartrate | 500 | $30,400 |
| LumiganBimatoprost | 74 | $25,751 |
| Prednisolone Acetate | 628 | $18,560 |
| Loteprednol Etabonate | 95 | $11,907 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 144 | $11,895 |
| RhopressaNetarsudil Mesylate | 31 | $10,504 |
| ProlensaBromfenac Sodium | 32 | $10,101 |
| CombiganBrimonidine Tartrate/Timolol | 46 | $9,672 |
| MoxifloxacinMoxifloxacin Hcl | 404 | $8,935 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $6,953 |
| VyzultaLatanoprostene Bunod | 25 | $6,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Lumigan, Combigan | $1,004 | $271,826711 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $500 | $79,20245 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $119 | $17,45749 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $163 | $6,55225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Los Angeles
- Steven JacobsonLos Angeles$4.7M
- David BoyerLos Angeles$4M
- Firas RahhalLos Angeles$1.2M
- Nicole FramLos Angeles$1.2M
- Andrew MoshfeghiLos Angeles$1M
- Pradeep PrasadLos Angeles$901K
- Barry SeibelLos Angeles$835K
- David LiaoLos Angeles$722K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.